Tnbc her2 neg stage 1 grade 3 28mm. Is carboplatin and docetaxel x 6 the correct regime?

The short version: for a 28 mm, grade 3, stage I, HER2-negative TNBC, the evidence for carboplatin plus docetaxel alone is thin and mostly indirect. The real question is whether you are being offered a regimen that was tested in a different stage or setting.

The evidence you were given does not contain a single trial that tested carboplatin plus docetaxel as adjuvant therapy for stage I TNBC. The closest study is a phase II neoadjuvant trial (stage II/III, not stage I) that added bevacizumab to the same backbone and reported a 42% pathologic complete response rate, but that trial was single-arm, funded by the manufacturer, and measured a surrogate endpoint (pCR), not survival [2]. The BCIRG 006 trial tested docetaxel plus carboplatin plus trastuzumab, but only in HER2-positive disease, not TNBC [3]. The CBCSG010 trial added capecitabine to a docetaxel-cyclophosphamide-epirubicin regimen and showed a 5-year DFS improvement from 80.4% to 86.3% (HR 0.66), but that regimen included an anthracycline and capecitabine, not carboplatin [9]. The SYSUCC-001 trial showed that low-dose capecitabine maintenance after standard treatment improved 5-year DFS from 73% to 82.8% (HR 0.64) [4]. The KEYNOTE-522 trial added pembrolizumab to carboplatin plus paclitaxel and showed a pCR improvement from 51.2% to 64.8% and an EFS hazard ratio of 0.63, but that was in stage II/III disease, not stage I, and included an anthracycline and immunotherapy [7, 8].

What is missing from the evidence is a direct test of carboplatin plus docetaxel alone in stage I TNBC. The standard of care for stage I TNBC has shifted toward anthracycline-taxane regimens, often with the addition of carboplatin and sometimes immunotherapy, but the evidence for de-escalating to a two-drug, non-anthracycline regimen in stage I is not established by these records. The Bulgarian real-world data shows that most early-stage TNBC patients receive anthracycline-taxane sequential regimens, not carboplatin-docetaxel alone [6].

The risk you face from the disease is real: TNBC has a higher relapse rate than other subtypes, with most recurrences happening within the first 24 months [5]. The 4-year relapse-free survival for TNBC in one study was 85.5% versus 94.2% for non-TNBC [1]. But the risk from the intervention includes substantial toxicity: in the neoadjuvant trial, grade 4 neutropenia occurred in 71% of patients and febrile neutropenia in 9% [2]. The capecitabine trials added hand-foot syndrome (45% all grades, 8% grade 3) [4, 9]. The pembrolizumab trials added immune-related adverse events leading to discontinuation in 30% of patients [7].

My call: carboplatin plus docetaxel for 6 cycles is not supported by direct evidence for stage I TNBC. The evidence that exists tests this regimen in higher-stage disease, with additional drugs, or in different subtypes. You should ask your oncologist for the specific trial that supports this regimen for your exact stage and subtype, and whether the standard has moved to include an anthracycline, capecitabine, or immunotherapy. Confidence: low.